Case number 1:23-cv-01456
Bayer Intellectual Property GMBH et al v. Umedica Laboratories Pvt. Ltd. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 27, 2024 | 10 | STIPULATION of Dismissal as to Defendant Umedica Laboratories Pvt, Ltd., filed by Bayer AG, Bayer Intellectual Property GMBH, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) Modified on 3/27/2024 (nms). (Entered: 03/27/2024) (2) |
| Mar 27, 2024 | 11 | SO ORDERED Granting (D.I. 252 in 21-md-3017-RGA-LDH; D.I. 10 in 23-cv-1456-RGA) Stipulation of Dismissal (*Party Umedica Laboratories Pvt. Ltd. and Umedica Laboratories Pvt. Ltd. terminated). Signed by Judge Richard G. Andrews on 3/27/2024. Associated Cases: 1:21-md-03017-RGA-LDH, 1:23-cv-01456-RGA(nms) (Entered: 03/27/2024) (2) |
| Mar 27, 2024 | N/A | CASE CLOSED per entry of D.I. 11 . (nms) (Entered: 03/27/2024) (0) |
| Mar 27, 2024 | 12 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,539,218 B2; 10,828,310 B2. (Attachments: # 1 Order)(nms) (Entered: 03/27/2024) (0) |
| Feb 1, 2024 | N/A | SO ORDERED, re 9 Unopposed Motion to Extend Time (*Reset Answer Deadlines: Umedica Laboratories Pvt. Ltd. answer due 4/29/2024). Signed by Judge Richard G. Andrews on 2/1/2024. (nms) (Entered: 02/01/2024) (0) |
| Jan 31, 2024 | 8 | SUMMONS Returned Executed by Bayer Intellectual Property GMBH, Janssen Pharmaceuticals, Inc., Bayer AG, Bayer Pharma AG.Umedica Laboratories Pvt. Ltd. served on 1/30/2024, answer due 2/20/2024. (Fahnestock, Derek) (Entered: 01/31/2024) (2) |
| Jan 31, 2024 | N/A | CORRECTING ENTRY: The motion filed at D.I. 9 has been removed from the docket as the filing was not duel captioned. This case is a member case to MDL 21-3017-RGA-LDH and therefore all filings need captions that include the MDL and the member case. Counsel is to refile the motion accordingly. (nms) (Entered: 01/31/2024) (0) |
| Jan 31, 2024 | 9 | Unopposed Motion to Extend Time - filed by Bayer AG, Bayer Intellectual Property GMBH, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) Modified on 2/1/2024 (nms). (Entered: 01/31/2024) (3) |
| Dec 27, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 12/27/2023) (0) |
| Dec 21, 2023 | 1 | Complaint* (1) |
| Dec 21, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) (Entered: 12/21/2023) (3) |
| Dec 21, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No earlier than November 14, 2023. Date of Expiration of Patent: U.S. Patent 9,539,218 expires February 17, 2034, with pediatric exclusivity to August 17, 2034, U.S. Patent 10,828,310 expires January 31, 2039, with pediatric exclusivity to July 31, 2039.Thirty Month Stay Deadline: 5/14/2026. (mkr) (Entered: 12/21/2023) (1) |
| Dec 21, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,539,218 B2; and 10,828,310 B2. (mkr) (Entered: 12/21/2023) (1) |
| Dec 21, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bayer AG for Bayer Intellectual Property GMBH, Bayer Pharma AG filed by Bayer AG, Bayer Intellectual Property GMBH, Bayer Pharma AG. (mkr) (Entered: 12/21/2023) (1) |
| Dec 21, 2023 | 6 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceuticals, Inc. filed by Janssen Pharmaceuticals, Inc. (mkr) (Entered: 12/21/2023) (1) |
| Dec 21, 2023 | 7 | Summons Issued as to Umedica Laboratories Pvt. Ltd. on 12/21/2023. (mkr) (Entered: 12/21/2023) (2) |
| Dec 21, 2023 | N/A | Remark: MDL panel has been advised. (mkr) (Entered: 12/21/2023) (0) |
